Compare Adaptive Biotechnologies Corp (ADPT) vs ProShares Ultra Silver ETF (AGQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ProShares Ultra Silver ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while ProShares Ultra Silver ETF trades at $81.4. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | AGQ | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $25.45 | $400.47 |
52-Week Low | $12.30 | $49.73 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
AGQ, a leveraged silver ETF, trades at $81.11, down 0.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights volatility, with articles noting a 9.39% surge on silver rallies but structural decay risks from daily-reset leverage. Financial ratios are unavailable as AGQ is an ETF tracking silver futures, not a company with fundamentals.
The outlook hinges on silver price momentum, offering amplified gains but high risk from leverage decay and silver volatility. Key risks include underperformance versus unlevered ETFs and sharp declines during silver sell-offs, as seen in a 16% drop in June 2026. Investors should weigh silver's bullish trend against ETF-specific drawbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →
